With the establishment of a pharmaceutical development strategy expert committee, Asymchem aims at expanding the company's domestic market, giving full play to the advantages of experts and scholars in order to form an intellectual synergy, actively promote Asymchem's green pharmaceutical technology progress and improve the professionalism and scientific level of strategic decisions.
Honorary President of the Chinese Pharmaceutical Enterprises Association
Yu Mingde is the Honorary President of the Chinese Pharmaceutical Enterprises Association. He has rich experience in medical production and distribution. Yu Mingde has served in roles of increasing responsibilities at the Fuxin Municipality Chemical Research Institute, Fuxin Pharmaceuticals Co., Ltd., Chinese Medicine Co., Ltd., as well as Director of the Fuxin Administration of Medical Products, and Director of Liaoning Province Administration of Medical Products. He also serves as Minister of Finance and Market Circulation for the National Administration of Medical Products, National Economy and Trade Administration, Minister of Medical Products, Deputy Director of the Economic Operations Bureau of the National Development and Reform Commission. Yu Mingde has also been invited to hold the position of Deputy Director of the Biomedical Expert Advisory Commission of the National Development and Reform Commission, as well as a member of the Major New Drug Panel of the Ministry of Science and Technology, the 13th Five Year Plan Panel of the Ministry of Industry and Information Technology, 09 Special Project Evaluation Panel of the Chinese Academy of Engineering. He is also a member of the advisory committee for the “Made in China 2025” plan.
Academician of the Chinese Academy of Sciences, Professor of the College of Chemistry, Nankai University
With a Ph.D in science, Zhou Qilin is a professor in the College of Chemistry at Nankai University, Cheung Kong Scholar of the Ministry of Education, and academician of the Chinese Academy of Sciences. His research interests include organic synthesis, organometallic chemistry, asymmetric catalysis, synthesis of bioactive compounds and chiral drugs. He discovered chiral spiro catalysts which show high activity and enantioselectivity in many asymmetric reactions, improving significantly the efficiency of the synthesis of chiral molecules. He was awarded the “Organic Synthesis Creation Award” by the Organic Chemistry Committee of the Chinese Chemical Society in 2005, the “Huang Yaozeng Organometallic Chemistry Award” by Chinese Chemical Society in 2006, the “Chiral Chemistry Award” by the Chinese Chemical Society in 2012. He was elected as a follow of the Royal Society of Chemistry in 2013. He won the Future Science Prize---Physical Science Prize in 2018 and the First Prize of the National Natural Science Award in 2019.
Former NMPA Chief Scientist, and FDA Senior Reviewer
Dr. Zengjun (Alex) Xu gained a bachelor’s degree in medicine in China and a PhD degree in Pharmacology and Toxicology in USA. He had his postdoctoral training at the National Center for Toxicological Research of the Food and Drug Administration (FDA). Dr. Xu worked at the Center for Drug Evaluation and Research of FDA (FDA/CDER) over 11 years as a Senior Reviewer in the Office of New Drugs (OND). He joined the Center for Drug Evaluation of NMPA (NMPA/CDE) in June 2017, as a Chief Scientist in the center for 3 years to promote the reform and improvement of the drug review system.
Special Vice President of the China Pharmaceutical Industry Association
Zhang Ziran, Ph.D. in Pharmaceutical Science, serves as Vice President of the China Pharmaceutical Industry Association, as well as Director of the Medical Policy and Regulation Committee, and Director of the Publicly Traded Pharmaceutical Companies Committee. He earned his master’s degree from West China University of Medical Sciences, followed by earning a doctoral degree at Shanghai University of Traditional Chinese Medicine, and pursued his MBA from the University of St Andrews, Scotland. Dr. Zhang established A&Z Pharmaceutical Inc. in the US and worked at Livzon Pharmaceutical Group Inc., Shanghai Pharma, and Shineway Pharma. following his return to China. He was an expert for the Drug Price Evaluation Center of National Development and Reform Commission.
President, Peking University School of Pharmaceutical Sciences
Dr. Zhou Demin is a professor and Dean of the School of Pharmaceutical Sciences, Peking University. He also serves as the Director of the State Key Laboratory of Natural and Biomimetic Drugs of China. He earned his bachelor’s degree from Beijing Medical University in 1990 and a joint Ph.D. degree from Beijing Medical University /University of Tsukuba, Japan in 1996. After 3 years teaching at the University of Tsukuba of Japan, Dr. Zhou went to the USA in 1999 for postdoctoral research at the University of California at Berkeley/The Scripps Research Institute. In 2002 he joined the American pharmaceutical industry, starting at Chugai-Roche as a senior scientist and then Immusol Inc. as a group leader and later division head. At the end of 2008, Dr. Zhou was recruited by Peking University as a full professor in China. He is currently a Yangtze River Scholars Distinguished Professor and the leading scientist for one of China’s “973 Project” His research area is to develop new chemicals and biotechnologies, based on integration of chemistry and biology, for improvement of the targeting and efficiency of anti-virus and anti-cancer drugs. The discovery of the “conversion of an infectious virus into a live-but-replication incompetent virus vaccine” has been named as “Paper of the Year” of the International Vaccine Society. Dr. Zhou serves as Associate Editor of Molecular Pharmaceutics and on the editorial board for several international journals including J Med Chem, Eur J Med Chem and Inter J Virology & AIDS.
Professor at Shanghai Jiao Tong University
Dr. Zhu has been awarded as Distinguished Expert of China since 2011 and appointed as “Zhi Yuan” Chair Professor, and Director of the Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, China. He received the “2017 National Award of Promoting Industry-University-Institute Collaboration”. Dr. Zhu received his degrees in biochemical engineering, microbial genetics, and MBA in China and the United States, then he spent his post-doctoral research at MIT and Harvard Medical School to develop his expertise for the career in biopharmaceutical development. Since 1987, Dr. Zhu played technical leadership roles 33 years, including 17 years with the Biopharmaceutical Development Program at Frederick National Laboratory for Cancer Research as director of technical operation.
Co-Chief Investment Officer & a partner at Hillhouse Capital Group
Michael Yi has been working with Hillhouse since the inception of the firm in 2005. Mr. Yi leads Hillhouse Capital’s healthcare investments in both public and private equities. He and his team have successfully invested in a great number of public companies. On private investment, his team has made investments into healthcare companies including Wuxi AppTec, BeiGene, Innovent, Junshi Biosciences, Ganlee, and dozens of innovative start-ups in biomedicine and medical devices in China and the United States, in addition to establishing Huimei Healthcare, a JV between Hillhouse and Mayo Clinic in China, in order to creating a “people-oriented ecosystem, focusing on support for innovative healthcare”. He holds an MBA from the Marshall School of Business at University of Southern California.
Corporate Vice President for Covance and General Manager for Covance China
Dr. Bi Honggang is a Ph.D. in chemistry and drug metabolism, Corporate Vice President for Covance and General Manager for Covance China. He is responsible for leading all Covance business and service activities in China including preclinical and clinical development, as well as central laboratory services; and representing Covance with various Chinese regulatory and government agencies. Since joining Covance in 2007, Dr. Bi has led the rapid growth of Covance China, expanding service offerings for local, regional and global clients. Dr. Bi has served in various leadership positions at various pharmaceutical companies such as SmithKline Beecham, Parke-Davis and Pfizer. Dr. Bi’s scientific achievements can be evidenced by more than 30 research publications and various presentations at scientific conferences.
Executive Producer of Healthcare Executive magazine series
Tan Yong started his career in medical media and information services in 2003. Now he is the producer of “Healthcare Executives” and “China County Health”, Secretary General of the China Healthcare Investment 50 Forum. Previously, he was the Deputy Editor in chief of “Medicine Economic Reporter”. Tan Yong is the author of “Main Stream-Wisdom of the China pharmaceutical Entrepreneurs” and “The Trilogy of Empowering China's Pharmaceutical Industry Transformation and Upgrading”. Tan Yong also oversaw the publishing of the book series “China's Pharmaceutical Industry Opinion Leader Papers”, which included “Aim at the First Legion of the China Pharmaceutical Industry”, “China Pharmaceutical Industry Reflections”, and “Apocalypse of the Pharmaceutical Giants”.